Cargando…
IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
Outcomes for patients diagnosed with the bone cancer osteosarcoma have not improved significantly in the last four decades. Only around 60% of patients and about a quarter of those with metastatic disease survive for more than five years. Although DNA-damaging chemotherapy drugs can be effective, th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085125/ https://www.ncbi.nlm.nih.gov/pubmed/27129149 http://dx.doi.org/10.18632/oncotarget.8980 |
_version_ | 1782463508846215168 |
---|---|
author | Shekhar, Tanmay M. Miles, Mark A. Gupte, Ankita Taylor, Scott Tascone, Brianna Walkley, Carl R. Hawkins, Christine J. |
author_facet | Shekhar, Tanmay M. Miles, Mark A. Gupte, Ankita Taylor, Scott Tascone, Brianna Walkley, Carl R. Hawkins, Christine J. |
author_sort | Shekhar, Tanmay M. |
collection | PubMed |
description | Outcomes for patients diagnosed with the bone cancer osteosarcoma have not improved significantly in the last four decades. Only around 60% of patients and about a quarter of those with metastatic disease survive for more than five years. Although DNA-damaging chemotherapy drugs can be effective, they can provoke serious or fatal adverse effects including cardiotoxicity and therapy-related cancers. Better and safer treatments are therefore needed. We investigated the anti-osteosarcoma activity of IAP antagonists (also known as Smac mimetics) using cells from primary and metastatic osteosarcomas that arose spontaneously in mice engineered to lack p53 and Rb expression in osteoblast-derived cells. The IAP antagonists SM-164, GDC-0152 and LCL161, which efficiently target XIAP and cIAPs, sensitized cells from most osteosarcomas to killing by low levels of TNFα but not TRAIL. RIPK1 expression levels and activity correlated with sensitivity. RIPK3 levels varied considerably between tumors and RIPK3 was not required for IAP antagonism to sensitize osteosarcoma cells to TNFα. IAP antagonists, including SM-164, lacked mutagenic activity. These data suggest that drugs targeting XIAP and cIAP1/2 may be effective for osteosarcoma patients whose tumors express abundant RIPK1 and contain high levels of TNFα, and would be unlikely to provoke therapy-induced cancers in osteosarcoma survivors. |
format | Online Article Text |
id | pubmed-5085125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-50851252016-10-31 IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα Shekhar, Tanmay M. Miles, Mark A. Gupte, Ankita Taylor, Scott Tascone, Brianna Walkley, Carl R. Hawkins, Christine J. Oncotarget Research Paper Outcomes for patients diagnosed with the bone cancer osteosarcoma have not improved significantly in the last four decades. Only around 60% of patients and about a quarter of those with metastatic disease survive for more than five years. Although DNA-damaging chemotherapy drugs can be effective, they can provoke serious or fatal adverse effects including cardiotoxicity and therapy-related cancers. Better and safer treatments are therefore needed. We investigated the anti-osteosarcoma activity of IAP antagonists (also known as Smac mimetics) using cells from primary and metastatic osteosarcomas that arose spontaneously in mice engineered to lack p53 and Rb expression in osteoblast-derived cells. The IAP antagonists SM-164, GDC-0152 and LCL161, which efficiently target XIAP and cIAPs, sensitized cells from most osteosarcomas to killing by low levels of TNFα but not TRAIL. RIPK1 expression levels and activity correlated with sensitivity. RIPK3 levels varied considerably between tumors and RIPK3 was not required for IAP antagonism to sensitize osteosarcoma cells to TNFα. IAP antagonists, including SM-164, lacked mutagenic activity. These data suggest that drugs targeting XIAP and cIAP1/2 may be effective for osteosarcoma patients whose tumors express abundant RIPK1 and contain high levels of TNFα, and would be unlikely to provoke therapy-induced cancers in osteosarcoma survivors. Impact Journals LLC 2016-04-25 /pmc/articles/PMC5085125/ /pubmed/27129149 http://dx.doi.org/10.18632/oncotarget.8980 Text en Copyright: © 2016 Shekhar et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Shekhar, Tanmay M. Miles, Mark A. Gupte, Ankita Taylor, Scott Tascone, Brianna Walkley, Carl R. Hawkins, Christine J. IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα |
title | IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα |
title_full | IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα |
title_fullStr | IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα |
title_full_unstemmed | IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα |
title_short | IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα |
title_sort | iap antagonists sensitize murine osteosarcoma cells to killing by tnfα |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085125/ https://www.ncbi.nlm.nih.gov/pubmed/27129149 http://dx.doi.org/10.18632/oncotarget.8980 |
work_keys_str_mv | AT shekhartanmaym iapantagonistssensitizemurineosteosarcomacellstokillingbytnfa AT milesmarka iapantagonistssensitizemurineosteosarcomacellstokillingbytnfa AT gupteankita iapantagonistssensitizemurineosteosarcomacellstokillingbytnfa AT taylorscott iapantagonistssensitizemurineosteosarcomacellstokillingbytnfa AT tasconebrianna iapantagonistssensitizemurineosteosarcomacellstokillingbytnfa AT walkleycarlr iapantagonistssensitizemurineosteosarcomacellstokillingbytnfa AT hawkinschristinej iapantagonistssensitizemurineosteosarcomacellstokillingbytnfa |